Carcinoma, Ovarian Epithelial research hub

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

This study looks at a new drug, oregovomab, combined with standard chemotherapy for women with advanced ovarian cancer after surgery. Researchers want to see if this combination works better and is safe compared to chemotherapy alone.